Intermediate AMD – Epidemiology Forecast – 2034

Intermediate AMD – Epidemiology Forecast – 2034

Key Highlights

AMD is a leading cause of severe vision loss in people over age 60. Intermediate AMD is a more critical distinction clinically because it places the individual at risk for progression to more advanced AMD.

In early dry AMD, symptoms are minimal, and the risk of advancing is low. However, in the intermediate stage, patients often face reduced visual acuity, colour vision issues, and dark adaptation challenges, with an increased risk of progressing to geographic atrophy (GA) or wet AMD.

The ForeseeHome AMD Monitoring Program by Notal Vision introduces a new option for monitoring a patient's vision at home. This at-home monitoring, offered by ForeseeHome, addresses concerns about missing the conversion from intermediate AMD to neovascular AMD. By enabling frequent monitoring for at-risk patients, it increases the chances of early detection of conversion to neovascular AMD, ultimately reducing the risk of vision loss post-conversion.

Individuals 65 years of age and older account for roughly 60% of intermediate AMD prevalent cases.

In 2023, the total prevalent cases of intermediate AMD in Japan were around 10,470,000 cases, and these cases are expected to increase during the forecast period.

DelveInsight’s “Intermediate AMD – Epidemiology – 2034” report delivers an in-depth understanding of Intermediate AMD, historical and forecasted epidemiology of Intermediate AMD in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Intermediate AMD Disease Understanding

Intermediate AMD Overview

Intermediate AMD represents a critical stage in the progression of this eye condition. Often asymptomatic or displaying minimal symptoms, individuals may experience distorted vision or central visual field loss. Notably, a heightened risk of progression to advanced AMD exists at this stage. Moreover, early detection and management are pivotal in preventing irreversible vision loss, making ongoing research crucial for addressing the challenges of intermediate AMD.

Intermediate AMD Diagnosis

Diagnosing Intermediate AMD involves identifying specific features like multiple medium drusen, at least one large druse, and non-center involving geographic atrophy. This stage may manifest mild visual changes, such as metamorphopsia or reduced visual acuity. Ophthalmologists use tools like the Amsler grid and conduct regular eye examinations for effective monitoring. As the intermediate stage poses a significant risk of progression to advanced AMD, accurate and timely diagnosis is crucial for implementing appropriate management strategies and preserving visual function. Diagnostic tests include visual acuity, dilated eye exams, Amsler grid, fluorescein angiography, and optical coherence tomography, contributing to accurate diagnosis and ongoing monitoring for timely interventions.

Further details related to diagnosis are provided in the report…

Intermediate AMD Epidemiology

The intermediate AMD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of intermediate AMD, diagnosed prevalent cases of intermediate AMD, and age-specific cases of intermediate AMD in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Among the 7MM, the US accounted for the highest prevalent cases of intermediate AMD in 2023, with around 19,861,500 cases; these cases are expected to increase during the forecast period.

Amongst EU4 and the UK, the total prevalent cases of intermediate AMD were highest in Germany, while the lowest number of cases were in Spain in 2023.

According to the estimates, in Japan, it is observed that intermediate AMD was most prevalent in the 65-84 years age group, accounting for over 45% of total cases in 2023.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the intermediate AMD evolving patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Retinal Specialist, ophthalmologist, eye specialist, and others.

DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centres such as the Institute for Saint John’s Health Centre in California, Byers Eye Institute, McPherson Eye Research Institute, Department of Ophthalmology, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or intermediate AMD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of intermediate AMD, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.

Comprehensive insight into the epidemiology segments and forecasts, and disease progression has been provided.

The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Intermediate AMD Report Insights

Patient Population

Country-wise Epidemiology Distribution

Age-wise cases of intermediate AMD

Intermediate AMD Report Key Strengths

Eleven Years Forecast

The 7MM Coverage

Intermediate AMD Epidemiology Segmentation

Intermediate AMD Report Assessment

Current Diagnostic Practices

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of intermediate AMD? What will be the growth opportunities across the 7MM concerning the patient population with intermediate AMD?

What is the historical and forecasted intermediate AMD patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Which age group of intermediate AMD has a high patient share?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the age-specific intermediate AMD prevalence cases in varying geographies over the coming years.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.